Innovative Medical Device Company XuanYu Medical Completes Two Consecutive Financing Rounds and Files IPO Prospectus

Investment Circle (ID: pedaily2012) April 2nd news, ShineyoMedical (Shanghai) Co., Ltd. (hereinafter referred to as "ShineyoMedical") announced the completion of consecutive rounds of financing byYifeng ZHUO HUATens of millions of yuan in A++ round financing andBaiyun Financial Investmenttens of millions of yuan in A+++ round financing. This round of financing will focus on the construction of marketing networks, the expansion of industrial bases, and the layout of innovative R&D pipelines, consolidating the leading position in the industry through a "technology + market" dual-drive approach.

ShineyoMedical was founded in May 2020, focusing on the fields of electrophysiology and peripheral vascular intervention. It has now built a 2,000-square-meter R&D center and a Class 10,000 cleanroom compliant with GMP standards for Class III medical devices in Shanghai, cumulatively obtaining nearly a hundred patents.

ShineyoMedical's self-developed multi-channel cardiac pulse field ablation system, consisting of the SHINERHYTHM® multi-channel cardiac pulse field ablation generator and the RHYTHPULSE® single-use cardiac pulse field ablation catheter, is compatible with mainstream cardiac electrophysiology 3D mapping systems. It is primarily used for the treatment of rapid arrhythmias by precisely delivering high-voltage pulses to myocardial tissue, causing irreversible electroporation in the target myocardial cells, thereby permanently isolating abnormal electrical signal conduction and restoring normal sinus rhythm to achieve therapeutic goals.

For obtaining this round of financing,Chen Shuguo, founder of ShineyoMedical, said:Thank You to Yifeng Capital, Baiyun Financial Holdings, and Existing Shareholders for Their Investment and Continued Recognition of ShineyoMedical. ShineyoMedical is Committed to Providing Clinically Innovative Solutions with Leading and Accessible Value for Doctors and Patients. The Approval of the PFA System Marks a Key Milestone in ShineyoMedical's Transition from a Research-Oriented Company to One Focused on Product Commercialization. Guided by Clinical Value, We Will Adopt a Model of ‘Precision R&D + Lean Manufacturing + Detailed Operations’ Driven by DFSS+DFM Design Philosophy to Create Differentiated Products That Meet Clinical Needs and Establish a Multi-Product Differentiation Matrix. Over the Next Three Years, We Aim to Launch and Begin Production and Sales of 15 Class III Medical Device Products. With the Support of Both New and Existing Shareholders, the Company Will Accelerate the Commercialization of Innovative Products and Scale Up Manufacturing. Within China’s Healthcare Ecosystem of DRG Payment and Volume-Based Procurement Linkage Management, We Will Pursue an Active Strategy of Cooperation and Development to Expand into Domestic and International Markets. We Believe This Will Enable Us to Successfully Navigate the Capital Winter and Achieve Sustainable Growth.

Zhang Chao, head of the Yifeng Zhuohua Fund, said:China has 12 million patients with atrial fibrillation (AF), with an annual surgical volume exceeding 150,000 cases. The market size of China's cardiac electrophysiology sector surpasses 10 billion yuan. The market share of pulsed field ablation (PFA) in global AF ablation is rapidly increasing, and the overseas market is expected to account for more than half in the short term, while the domestic market is still in its early stages. ShineyoMedical has positioned itself in multiple high-demand areas such as electrophysiology, varicose veins, and pulmonary embolism, with its core products advancing at a leading pace domestically. The team boasts rich industry experience, strong product capabilities, and years of deep industry cultivation, with PFA commercialization on the horizon. As a market-oriented fund established with contributions from Hubei Province’s Chutian Fengming Fund, Wuhan Industrial Fund, Jiangxia Science & Technology Investment, and other investment institutions at the provincial, city, and district levels in Hubei, we have confidence in ShineyoMedical’s innovative product portfolio. We believe that under the leadership of its founder, ShineyoMedical will become one of China’s outstanding innovative medical device companies.

The investment director of Baiyun Financial Holdings said:We are optimistic about ShineyoMedical's focus on high-performance medical devices, driven by clinical (market) needs, and its continuous advancement in the research, development, and commercialization of cutting-edge medical devices. Through breakthroughs in both R&D efforts and market penetration, ShineyoMedical is building a competitive moat with both technological barriers and scale effects. As the state-owned industrial finance platform of Baiyun District, Guangzhou, Baiyun Finance Holdings is pleased to have the opportunity to support the domestic substitution of high-end medical devices and the development of innovative technologies in China.